AbbVie’s $11 Billion Bet on Oncology: Acquiring Apogee Therapeutics
AbbVie’s $11 Billion Bet on Cancer Innovation
AbbVie Takes the Leap: Why the $2.5 B Buy‑out of Apogee Therapeutics Could Redefine Immunology